Clinical Genetics Has a Big Problem That's Affecting People's Lives
By Ed Yong,
The Atlantic
| 12. 17. 2015
Untitled Document
For Heidi Rehm, it looked like a straightforward case. Her lab at Partners Healthcare offers tests for genetic diseases. They had received a blood sample from a fetus after a doctor conducting an ultrasound spotted signs of Noonan syndrome—an inherited disorder involving heart problems and stunted growth. The fetus turned out to have a mutation in PTPN11, a gene that affects the risk of Noonan syndrome.
Rehm found that another team of scientists had published on that very same mutation before. (Not every mutation of PTPN11 increases the rick of Noonan syndrome.) They found that it was more common among Noonan patients than in healthy people, and had billed it as “pathogenic”—that is, likely to cause disease. Rehm reported it as such to the doctor who sent her the sample.
Sometime later, she was listening to a talk by a colleague who had found the same mutation in a patient with Noonan syndrome and, based on the same published study, had also classified it as pathogenic. But this time, the patient—an adult—had contacted the researchers behind...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...